Trinity Biotech (TRIB) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Fiserv president resigns, interim leaders named for financial unit
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Trinity Biotech announces Quarter 3 Financial Results
October 25, 2016 8:15 AM EDTDUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2016.
Quarter 3 Results                                                                                          Total revenues for Q3, 2016 were $26.1m which compares to $25.8m in Q3, 2015, an increase of 1.4%.
Point-of-Care revenues for Q3, 2016 decreased from $5.4m to $4.9m when compared to Q3, 2015, a decline of 9.5%. This is within the normal quarterly fluctuation range of HIV sales in Africa.
Clinical Laboratory revenues increased to $21.2m, which represents an... More
